Revolution Medicines Receives FDA Breakthrough Designation, Royalty Pharma Offers a Diversified Investment Path Sep 25, 2026 Life Science
BMY vs. JNJ: Low Valuation and High Yield or High Profit and Steady Growth? Sep 24, 2026 Life Science
AI Finds New Clues for Gene Editing, but It Is Still Far from a “New CRISPR” Sep 23, 2026 Life Science
Positive VK2735 Clinical Data: Can Viking Therapeutics Displace Eli Lilly and Novo Nordisk? Sep 23, 2026 Life Science
Iambic Therapeutics Files for U.S. IPO, Adding Another AI Drug-Discovery Startup to Nasdaq Pipeline Sep 22, 2026 Life Science, Technology
Johnson & Johnson Accelerates Divestiture of DePuy Synthes, Investors Optimistic About Streamlined Strategy Sep 22, 2026 Life Science
Eli Lilly Stock Trails the Market, and Its Growth Story Faces a Test Under a High Valuation Sep 21, 2026 Life Science
Eli Lilly’s Leading Position in the Weight-Loss Drug Market Remains Solid, Competition Landscape for Oral Drugs Begins to Emerge Sep 19, 2026 Life Science
Johnson & Johnson vs. Kenvue, Which Is Better Suited for a Defensive Dividend Portfolio? Sep 17, 2026 Life Science
From the Financial Crisis to the 2022 Bear Market, How Does Amgen Demonstrate Resilience? Sep 17, 2026 Life Science
Can Novo Nordisk’s Anthropic Partnership Drive an AI-Powered Turnaround? Sep 16, 2026 Life Science, Technology
Investors Seek Buying Opportunities Before Year-End, These Two Stocks Are Cheaply Valued and Offer Growth Potential Sep 16, 2026 Financial Service, Life Science
Eli Lilly Ramps Up Acquisitions to Diversify Beyond Weight-Loss Drug Dominance Sep 15, 2026 Life Science
Novartis Suffers Three Clinical Setbacks in a Row, So Why Has Eli Lilly Avoided the Vortex? Sep 15, 2026 Life Science
Amgen vs. Vertex Pharmaceuticals: Value Stability vs. High-Growth Biotech Investment Plays Sep 14, 2026 Life Science
Johnson & Johnson Advances Spin-Off and Sale in Parallel as Orthopedics Business Valued at Nearly $20 Billion Sep 11, 2026 Life Science
